The Australian Government is now in caretaker period. During this time, updates on this website will be published in accordance with the Guidance on Caretaker Conventions, until after the election.
2709 results found
NHMRC takes all research integrity matters very seriously. All research we fund is required to comply with the Australian Code for the Responsible Conduct of Research, 2018 (the Code).
Professor Patrick Sexton is the Professor of Pharmacology at the Monash Institute of Pharmaceutical Sciences and is the Director at the ARC Centre for Cryo-electron Microscopy of Membrane Proteins. Professor Sexton is a leader in progressing our understanding of G protein-coupled receptors (GPCRs), particularly allosteric modulation and biased agonism, and applying cryo-EM to study structure and dynamics of GPCRs. He is a Clarivate Analytics highly cited researcher and an elected Fellow of the British Pharmacological Society (BPS). Professor Sexton is also the co-founder of Septerna Inc and DACRA Tx and has been the recipient of many awards for his scientific contributions that have had major impacts on biological chemistry research.
The NHMRC Corporate Plan 2024-25 presents our strategy for building a healthy Australia, across the strategic themes (purposes) of investment, translation and integrity of health and medical research. The plan also includes our strategic and health priorities, as well as our key activities planned for 2024–25 and over the next few years. The plan describes the operating context in which we work and outlines our performance criteria and targets for the next 4 years.
Aboriginal and Torres Strait Islander health evidence-practice policy gap reports. An evidence-practice/policy gap is the difference between what is known from the best available research evidence and what is practised in reality (through delivery of medical care or drafting of policies or guidelines).
The NHMRC Corporate Plan 2020-21 covers the four years to 2023-24. In line with legislated requirements, it identifies major health issues likely to arise, how NHMRC will deal with these issues (including the continuing impact of COVID-19) and our strategy for health and medical research. It also details the key activities NHMRC will undertake to achieve our purposes, and the operating context in which we work, comprising: environment, capability, risk oversight and management, and organisations NHMRC cooperates with to achieve our purposes.
This consultation report provides the outcomes of NHMRC’s national consultation on options to reach gender equity in the Investigator Grant scheme.
NHMRC has developed advice that is designed to provide information for researchers and reviewers of research to assist in decision-making about when payment of participants in research is ethically acceptable.
MRFF – Cardiovascular Health Mission - 2024 Cardiovascular Health Grant Opportunity